阿托伐他汀对不稳定型心绞痛患者高敏C反应蛋白的影响

Atorvastatin treatment of patients with unstable angina and the impact on high-sensitivity C-reactive protein

目的探讨阿托伐他汀对不稳定型心绞痛患者高敏C反应蛋白的影响。方法 56例UAP患者随机分为观察组和对照组各28例,两组患者均予吸氧、卧床休息,严密监护,其中对照组予硝酸盐、低分子肝素、β受体阻滞剂以及钙通道拮抗剂等。观察组在对照组的基础上予阿托伐他汀8～10 mg/d,每日睡前一次,疗程8周,根据病情变化调整剂量。比较两组治疗后的疗效及两组患者治疗前后不同时间hs-CRP的变化。结果观察组的总有效率达93.9%,明显高于对照组(P<0.05)。观察组与对照组治疗4周后、治疗8周后血清hs-CRP均较治疗前明显降低,且观察组降低程度明显低于对照组(P<0.05)。结论阿托伐他汀治疗不稳定型心绞痛疗效确切,且可以降低hs-CRP。

Objective To investigate the atorvastatin treatment of patients with unstable angina, and the impact on high sensitivity C-reactive protein. Methods All of 56 patients with UAP patients were randomly divided into observation group and control group 28 cases, two groups of patients herein were given oxygen, bed rest, intensive care, nitrates, low molecu lar weight heparin, 13 receptor blockers and calcium channel antagonists. The observiation group on the basis of the control group were given atorvastatin （Lipitor, Pfizer） 8 to 10 rag/d, a day before bed time for 8 weeks, dosage adjustment based on changes in condition. The efficacy of two groups of patients before and after different times of the changes of hs-CRP were compared between the two groups after treatment. Results The total effective rate of the observation group was 93.9%, and was significantly higher （P 〈 0.05）. after treatment 4 weeks, serum hs-CRP in the observation group and control group was significantly reduced than those before treatment after 8 weeks of treatment, and the observation group reduced significantly lower than the control group （P 〈 0.05）.Conclusion Atorvastatin treatment unstable Angina is exact, and can decrease of hs CRP.